

Atty Dkt 0800-0026  
PATENT

JC997 U.S. PTO

09/932451



"Express Mail" Mailing Label No. EL 873 906 628, Date of Deposit 17 August 2001.  
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail  
Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed  
to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Susan LaMont  
(Typed or Printed Name of Person Mailing Paper or Fee)

Susan LaMont  
(Signature of Person Mailing Paper or Fee)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

OZAWA et al.

Serial No.: Unassigned

Group Art Unit: Unassigned

Filing Date: Even Date Herewith

Examiner: Unassigned

Title: ADENO-ASSOCIATED VIRUS-MEDIATED DELIVERY OF  
ANGIOGENIC FACTORS

### INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

The information listed below may be material to the examination of the above-identified application. Copies of the information and completed PTO-1449 forms are submitted herewith. The Examiner is respectfully requested to make this information of official record in the application. The information includes:

United States Patent No. 5,858,351 issued Jan. 12, 1999 to Podsakoff *et al.*;

United States Patent No. 6,211,163 issued Apr. 3, 2001 to Podsakoff *et al.*;

Asahara, *et al.*, "Accelerated restitution of endothelial integrity and endothelium-dependent function after phVEGF165 gene transfer," *Circulation* 94:3291-3302 (1996);

Podsiadly, *et al.*, "Effect of endothelial growth factor on collateral blood flow to

Baumgartner, *et al.*, "Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia," *Circulation* 97:1114-1123 (1998);

Ferrara, *et al.*, "Molecular and biological properties of the vascular endothelial growth factor family of proteins," *Endocr. Rev.* 13:18-32 (1992);

Guzman, *et al.*, "Efficient gene transfer into myocardium by direct injection of adenovirus vectors," *Circ. Res.* 73:1202-1207 (1993);

Hariawala, *et al.*, "VEGF improves myocardial blood flow but produces EDRF-mediated hypotension in porcine hearts," *J. Surg. Res.* 63:77-82 (1996);

Henry, *et al.*, "Double blind, placebo controlled trial of recombinant human vascular endothelial growth factor—the VIVA Trial," *J. Am. Coll. Cardiol.* 33:384A (1999);

Hojo, *et al.*, "Expression of vascular endothelial growth factor in patients with acute myocardial infarction," *J. Am. Coll. Cardiol.* 35:968-973 (2000);

Isner, *et al.*, "Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb," *Lancet.* 348:370-374 (1996);

Leung, *et al.*, "Vascular endothelial growth factor is a secreted angiogenic mitogen," *Science* 246:1306-1309 (1989);

Losordo, *et al.*, "Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia," *Circulation* 98:2800-2804 (1998);

Mack, *et al.*, "Salvage angiogenesis induced by adenovirus-mediated gene transfer of vascular endothelial growth factor protects against ischemic vascular occlusion," *J. Vasc. Surg.* 27:699-709 (1998);

Mack, *et al.*, "Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121

Maeda, *et al.*, "Gene transfer into vascular cells using adeno-associated virus (AAV) vectors," *Cardiovasc. Res.* 35:514-521 (1997);

Maeda, *et al.*, "Efficient gene transfer into cardiac myocytes using adeno-associated virus (AAV) vectors," *J. Mol. Cell Cardiol.* 30:1341-1348 (1998);

Maeda, *et al.*, "Adeno-Associated Virus-Mediated Vascular Endothelial Growth Factor Gene Transfer in to Cardiac Myocytes," *J. Cardiovasc. Pharmacol.* 36:438-443 (2000);

Magovern, *et al.*, "Direct in vivo gene transfer to canine myocardium using a replication-deficient adenovirus vector," *Ann. Thorac. Surg.* 62:425-433 (1996);

Muhlhauser, *et al.*, "VEGF165 expressed by a replication-deficient recombinant adenovirus vector induces angiogenesis in vivo," *Circ. Res.* 77:1077-1086 (1995);

Neufeld, *et al.*, "Vascular endothelial growth factor (VEGF) and its receptors," *FASEB J.* 13:9-22 (1999);

Rosengart, *et al.*, "Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease," *Circulation* 100:468-474 (1999);

Shibuya, *et al.*, "Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family," *Oncogene* 5:519-524 (1990);

Shulick, *et al.*, "In vivo gene transfer into injured carotid arteries. Optimization and evaluation of acute toxicity," *Circulation* 91:2407-2414 (1995);

Springer, *et al.*, "VEGF gene delivery to muscle: potential role for vasculogenesis in adults," *Mol. Cell* 2:549-558 (1998);

Svensson, *et al.*, "Efficient and stable transduction of cardiomyocytes after intramyocardial injection or intracoronary perfusion with recombinant adeno-associated virus vectors," *Circulation* 99:201-205 (1999);

Takeshita, *et al.* "Therapeutic angiogenesis. A single intraarterial bolus of

Tsurumi, *et al.*, "Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion," *Circulation* 94:3281-3290 (1996).


This Information Disclosure Statement under 37 CFR § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

Respectfully submitted,

Date:

8/17/01

By:



Roberta L. Robins  
Registration No. 33,208

ROBINS & PASTERNAK LLP  
90 Middlefield Road, Suite 200  
Menlo Park, CA 94025  
Telephone: 650-325-7812  
Facsimile: 650-325-7823